Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. - Wikidata - wikimedia - TriplyDB

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.

http://www.wikidata.org/entity/Q37681718

about

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Clinical Development of Immune Checkpoint Inhibitors.Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.Harnessing the immune system for the treatment of melanoma: current status and future prospects.Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.Distinct histone modifications denote early stress-induced drug tolerance in cancer.Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

P2860

Q26785746-ED33B0DD-18F0-4AF4-ADD2-617C41446ED7 Q26996518-A41C4A85-AB9A-413D-A127-112AC9E8948C Q34671498-43F8C7E3-DFC7-495F-B71F-52F380E9D002 Q36028546-36946A69-51B5-4065-8785-C6D2253FAC56 Q37091138-05B80B8E-F2D5-47E7-8A2E-C928FA841F4D Q37188758-259AF314-F34C-456D-AF2D-E9F17468E614 Q38806243-A8FB94C5-12EE-4D3B-B9FC-5A687878191F Q47688850-EA713C3B-DCC7-49DA-91BE-C8C84E29EB3E Q50318225-D6E9901B-74D9-4DBB-B58E-40F4DC8DB1DB Q51183314-4199F4D7-3E0D-41B2-AC0F-5C502E70788C Q52648405-78BB9AC3-A7D4-46D2-A5C6-0F7073E100B9 Q56896166-38E51915-1A05-492A-B6AE-40D80C97ECEE Q58767976-17365944-58BF-4438-B85E-8705B27144B6

P2860

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.

http://www.wikidata.org/entity/Q37681718

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@en

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@nl

type

label

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@en

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@nl

prefLabel

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@en

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@nl

P1433

Q37681718-42BB63BE-31C8-42AC-9807-DEE1EB20584B

P1476

Q37681718-2179491C-2535-4793-A1E1-7BEF058C5E75

P2093

Q37681718-06E5E278-E3F3-4C24-9641-5088819E7422

Q37681718-293ADE19-B230-4E27-A5C9-459986839431

Q37681718-43279A91-65D1-4169-BB0A-67E6B3920ADB

Q37681718-51FF9E6B-2ACB-4320-95FF-85306B12FF51

Q37681718-757A1D68-4546-4CC3-94C6-4761C275F87D

Q37681718-CF014238-5CEC-443A-8710-86CE4C3E1D8A

P2860

Q37681718-057FAD9F-B790-41F6-B314-35C12595E540

Q37681718-10544D0D-3C6E-4F51-B634-1D41140D5200

Q37681718-2072F9EA-1B60-425D-9A03-8615861D45BF

Q37681718-35055C3C-3181-47D0-A143-CC6AA1202D2D

Q37681718-4C72C7F9-8305-40C9-9D26-1D5823194DB5

Q37681718-59F6163C-47C4-4DA1-A3F9-7CD51D03F83B

Q37681718-5BAC58E2-EE0D-493F-95EB-FFB18738A946

Q37681718-5BF89DD0-FD25-40C5-A7F8-622E460B1AE8

Q37681718-659726D2-F45C-4FCC-8C6E-5F47F96688AB

Q37681718-78A500F2-77DE-40BF-A225-F432F26139A4

P2888

Q37681718-07BFD804-ED2D-49E5-922E-F1ADB9F082F2

P304

Q37681718-44EF5F0F-DEDC-46E5-B4D6-C3A7CC83048F

P31

Q37681718-87F97FED-B24E-498D-AEC5-E76A7F104281

P356

Q37681718-E6BC60BF-E72D-4AEC-9D65-98D9DF3A4FA4

P407

Q37681718-F488B2E0-BFD2-4CA8-9579-B867BFE8974B

P433

Q37681718-9AA3A9A9-E424-4221-8C53-90821195CDEE

P478

Q37681718-046BCEA8-30C2-436F-8BD5-C0FD5370C644

P50

Q37681718-2B9BE86A-01C8-45D5-9F33-FE7F4D27D118

Q37681718-38DB8ABC-FC81-45AF-A7A9-B0CB9E9F736C

Q37681718-3A38012E-ED6A-45F7-829F-7F90CEC3ECA9

Q37681718-56E0892C-E41C-4EF0-944C-15441A8EC06E

Q37681718-674B43C7-ED5C-43AB-B8A5-F32FF898F8C8

Q37681718-9C795BDA-DAFE-492C-A041-5C5EF5467CDA

Q37681718-AD3DD102-0698-4371-8FDD-577EE5246A1C

Q37681718-B686481B-0DF9-4C02-A7DE-A422BBB9253B

Q37681718-C26643C1-4003-4821-98A6-92B6AE04FAF3

Q37681718-F133D8C6-B845-4CD1-8D96-51DFB0C4FC34

P577

Q37681718-5A30CBF2-52F9-4C37-96CE-DA8EF83F794E

P5875

Q37681718-18BA3D73-3AFE-41D4-A43A-9AB797E1963C

P6179

Q37681718-6DB13A08-397A-4FE0-8CC0-6D5B400526F1

P698

Q37681718-89365D73-14D1-4403-9FAB-878C48C8B785

P921

Q37681718-393CB399-0BD3-4EA2-8FCE-3B2EE4E8DD0D

Q37681718-73CBDFE9-82EB-4705-9A6F-9F0D46C78379

P932

Q37681718-3FCA984B-4D41-4D12-9630-7BF08649B600

P356

P1433

British Journal of Cancer

P1476

Ipilimumab retreatment in pati ...... ded access programme in Italy.

@en

P2093

E Simeone

http://www.w3.org/2001/XMLSchema#string

F Carnevale Schianca

http://www.w3.org/2001/XMLSchema#string

F De Galitiis

http://www.w3.org/2001/XMLSchema#string

M Mandalà

http://www.w3.org/2001/XMLSchema#string

P A Ascierto

http://www.w3.org/2001/XMLSchema#string

P Quaglino

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

Reversal of the TCR stop signal by CTLA-4

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Estimates of cancer incidence and mortality in Europe in 2008.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

P2888

P304

1721-1726

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.126

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Michele Del Vecchio

Pier Francesco Ferrucci

Paolo Marchetti

Lorenza Di Guardo

Francesco Spagnolo

V Chiarion-Sileni

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260717311

http://www.w3.org/2001/XMLSchema#string

P6179

1014968763

http://www.w3.org/2001/XMLSchema#string

P698

24619072

http://www.w3.org/2001/XMLSchema#string

P921

P932

3974075

http://www.w3.org/2001/XMLSchema#string